{"product_id":"abcam-ab255824","title":"Abcam, ab255824, Anti-Factor IX\/PTC antibody [EPR22846-238]","description":"\u003cp\u003eSize: 100µL \/ 1mL\u003cbr\u003e\nRabbit Recombinant Monoclonal Factor IX\/PTC antibody. Suitable for IP, WB and reacts with Human samples. Cited in 3 publications.\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Monoclonal,\u003cbr\u003e\nClone number:EPR22846-238,\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:No,\u003cbr\u003e\nReacts with:Human,\u003cbr\u003e\nApplications:WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nWhat are the advantages of a recombinant monoclonal antibody?\u003cbr\u003e\nThis product is a recombinant monoclonal antibody, which offers several advantages including:\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nFor more information, read more on\u003cbr\u003e\nrecombinant antibodies\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze \/ thaw cycle\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nFactor IX also known as Christmas factor or PTC is an important clotting protein in the coagulation cascade. It is a 415 amino acid protein with a mass of approximately 55 kDa. Factor IX is mainly expressed in the liver and then released into the bloodstream where it plays a significant role in blood clotting processes. The recombinant version of this protein referred to as factor IX recombinant is used therapeutically especially in patients who require coagulation support due to factor deficiencies.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nThe function of factor IX involves its role in the amplification phase of the coagulation cascade. It participates as part of the intrinsic tenase complex which forms on negatively charged phospholipids in the presence of calcium ions. This complex significantly enhances the conversion of factor X to its active form factor Xa an important step in the clotting process. The activity of factor IX can be assessed using assays such as the factor IX activity assay and ELISA allowing for precise measurement of its function and quantity.\u003cbr\u003e\nPathways\u003cbr\u003e\nFactor IX is integral within the intrinsic pathway of blood coagulation. It interacts with proteins such as factor VIII and factor X. When activated factor IXa forms a complex with the cofactor factor VIIIa on membrane surfaces intensifying the transformation of factor X to factor Xa which then catalyzes the conversion of prothrombin to thrombin. This series of reactions leads to fibrin formation important for stable clot production. Factor IXa also relates to the pathways influencing cellular signaling and hemostasis.\u003cbr\u003e\nFactor IX deficiencies cause hemophilia B a genetic disorder that leads to improper blood clotting. This disorder is mainly characterized by spontaneous bleeding or severe bleeding after injury. Patients with hemophilia B usually have mutations in the factor IX gene on the X chromosome affecting the protein's function. Successful treatment often involves replacement therapy using factor IX concentrates or the recombinant form. The interaction with proteases such as factor VIIa highlights its importance in therapeutic strategies for bleeding disorders.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46855910195369,"sku":"ab255824","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/abcam-ab255824","provider":"Iright","version":"1.0","type":"link"}